Gossamer Bio, Inc. (GOSS)
| Market Cap | 641.23M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -243.36M |
| Shares Out | 68.51M |
| EPS (ttm) | -3.55 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 19 |
| Last Price | $8.25 |
| Previous Close | $8.49 |
| Change ($) | -0.24 |
| Change (%) | -2.83% |
| Day's Open | 8.43 |
| Day's Range | 8.22 - 8.47 |
| Day's Volume | 146,343 |
| 52-Week Range | 7.92 - 16.79 |
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the ...
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the ...
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the ...
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease ar...
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the ...
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease ar...
Gossamer Bio, Inc. (GOSS) CEO Sheila Gujrathi on Q3 2020 Results - Earnings Call Transcript
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the ...
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the ...
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the ...
These are the stocks seeing the most insider buying this week
In his weekly exclusive for Worldwide Exchange, Brian Sullivan highlights three stocks seeing the most insider buying this week, including some biotech names.
Cerus Inks FDA Contract, And Other News: The Good, Bad And Ugly Of Biopharma
Investors reacted forcefully Tuesday after Gossamer Bio Inc.'s (NASDAQ:GOSS) drug designated GB001 failed to achieve the hoped-for outcome in a study of patients with asthma and chronic sinus inflammati...
Gossamer Bio Inc. (NASDAQ: GOSS) shares dived on Tuesday after the company announced midstage results from its asthma and chronic rhinosinusitis studies.
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease ar...
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), today announced multiple updates for its GB004 program. GB004 is an oral, gut-targeted HIF-1α stabilizer, designed to promote mucosal heali...
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the ...
Investors need to pay close attention to Gossamer Bio (GOSS) stock based on the movements in the options market lately.
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease ar...
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease ar...
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the ...
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the ...
As of late, it has definitely been a great time to be an investor in Gossamer Bio.
NEW YORK, May 20, 2020 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Gossamer Bio, Inc. ("Gossamer" or the "Company")(NASDAQ:GOSS) of the June 2, 202...
Stock dilution is on the way for the small biotech.
Gossamer Bio, Inc. (GOSS) CEO Sheila Gujrathi on Q1 2020 Results - Earnings Call Transcript
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
As of late, it has definitely been a great time to be an investor Gossamer Bio
Gossamer Bio (GOSS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Gossamer Bio Inc (NASDAQ: GOSS) shares are tumbling to their lowest level since Oct.
Shares of biotech company Gossamer Bio tumbled in high volume Monday after rival pharmaceutical company Novartis scrapped an asthma treatment that failed to meet its goal in a Phase 3 study. The post T...
Novartis is throwing in the towel on a drug similar to Gossamer's lead candidate.
Gossamer Bio, Inc. (GOSS) CEO Sheila Gujrathi on Q3 2019 Results - Earnings Call Transcript
Fresh off an initial public offering, the pharmaceutical company has taken investors on a wild ride.
About GOSS
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2, which is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma; in Phase II clinical trial to treat patients with chronic rhinosinusitis with and without nasal polyps; and in Phase 2 clinical trial in patients wi... [Read more...]
| Industry Biotechnology | IPO Date Feb 8, 2019 |
| CEO Sheila Gujrathi | Employees 195 |
| Stock Exchange NASDAQ | Ticker Symbol GOSS |
Analyst Forecasts
According to 7 analysts, the average rating for Gossamer Bio stock is "Buy." The 12-month stock price forecast is 21.00, which is an increase of 154.55% from the latest price.